Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy

Ma, Xiaodong; Özliseli, Ezgi; Zhang, Yuezhou; Pan, Guoqing; Wang, Dongqing; Zhang, Hongbo

doi:10.1039/c8bm01333k

Cited by 55 publications

(38 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For covalent conjugation method, a lot of anticancer drugs have been investigated to prepare the amphiphilic drug-drug conjugates, including irinotecan-doxorubicin conjugate, 47,48 floxuridine-bendamustine conjugate, 49 irinotecan-HIF-1α conjugate, 50 methotrexate-CPT conjugate, 51 irinotecan-bendamustine conjugate, 52 irinotecan-chlorambucil conjugate, 22 gemcitabinechlorambucil conjugate, 22,53 CPT-floxuridine conjugate, 54 gemcitabine-CPT conjugate, [55][56][57] methotrexate-CPT conjugate, 58 methotrexate-doxorubicin conjugate, 58 CPTirinotecan conjugate, 59 irinotecan-enediyne conjugate, 60 doxorubicin-paclitaxel conjugate, 61 and floxuridinepseudolaric acid B conjugate. 62 Most of these amphiphilic drug-drug conjugates can directly assemble into nanoparticles in water for cancer therapy.…”

Section: Drug-drug Conjugatesmentioning

confidence: 99%

“…62 Most of these amphiphilic drug-drug conjugates can directly assemble into nanoparticles in water for cancer therapy. Interestingly, Zhang et al 61 reported the preparation of doxorubicin-paclitaxel prodrug nanoparticles with microfluidics. Many of these nanodrugs showed synergistic anticancer efficacy and some of them even could overcome the multidrug resistance of tumor cells.…”

Section: Drug-drug Conjugatesmentioning

confidence: 99%

See 1 more Smart Citation

Engineering small molecule nanodrugs to overcome barriers for cancer therapy

Mou

Yan

et al. 2020

VIEW

View full text Add to dashboard Cite

Small molecule nanodrugs consisting of pure drugs, drug‐drug dimers, drug‐drug conjugates, or drug derivatives could realize drug delivery by themselves without the aid of carriers, which have received abundant attention in recent decades. Avoiding the use of additional carriers, the yielded small molecule nanodrugs hold the following advantages: (a) high drug loading capacities (some of them could even reach up to 100%); (b) precise and tunable drug loading ration; and (c) no carrier‐induced long‐term toxicity. The past decade has witnessed rapid growth and advancements in this field. In this review, we will briefly introduce both in vitro “barriers” and in vivo barriers for drug delivery, and then summarize the most recent development of small molecule nanodrugs from the point of view how to engineer small molecule nanodrugs to overcome these barriers.

show abstract

Section: Drug-drug Conjugatesmentioning

confidence: 99%

Section: Drug-drug Conjugatesmentioning

confidence: 99%

Engineering small molecule nanodrugs to overcome barriers for cancer therapy

Mou

Yan

et al. 2020

VIEW

View full text Add to dashboard Cite

show abstract

“…Nevertheless, direct applications of the antibody as a drug for oncotherapy may result in serious cytokine storm. To avoid this situation, proper drug delivery systems, such as nanoparticles [13][14][15][16][17][18][19], microparticles [20][21][22][23][24][25][26] or hydrogels [27][28][29][30][31][32][33] are employed for reducing drug toxicity and inhibiting the multi-drug resistance. However, the problems that come with these nano-carriers are the insufficient efficacy due to their short action time at tumor site, and the excessive systemic immune response because of the easy-spreading blood circulation; whereas the bulk delivery systems are not applicable for controllable drug release, substance exchange with outer environment, and flexible implantation since their relatively larger size and simple structure.…”

Section: Introductionmentioning

confidence: 99%

Immunotherapeutic silk inverse opal particles for post-surgical tumor treatment

et al. 2020

View full text Add to dashboard Cite

“…Nanomedicines that respond to pH [11,12], temperature [13], light [14], redox state [15], magnetic elds [16,17], biomolecules [18], or combinations thereof have been developed and proved. The clinical success of nanoparticle-based therapy illustrates the power of this approach.…”

Section: Introductionmentioning

confidence: 99%

Redox-Responsive Tumor Targeted Dual-Drug Loaded Biocompatible Metal-Organic Frameworks for Enhancing Anticancer Cytotoxicity

Liu¹,

Xu²,

Zhou³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Abstract Metal-organic frameworks (MOFs) have proven to be a promising class of drug carriers due to their high porosity, crystalline properties with defined structure information, and their potential for further functionalization. However, to date, no extensive research has been conducted on MOF-based drug carriers with stimuli-responsive, dual-drug delivery, and tumor targeting functions. Here, we demonstrate the strategy of constructing a redox responsive and tumor-targeted MOF, as dual-drug carrier, by anchoring functional disulfide anhydride and folic acid (FA) molecules to the organic links of MOFs, respectively. The MOF composites show the controlled release of loaded 5-fluorouracil (5-FU) entrapped within UiO-66-NH2 nanostructures modified by dichloroacetic acid (DCA). Moreover, the MOF building block DCA acts as a synergistical drug to 5-FU in cancer cells inhibition. Through disulfide bonds, the gated MOF has redox-responsive drugs release. The confocal laser scanning microscopy further proved that conjugation of folic acid to the MOF surface can significantly enhance the targeting ability to cancer cells and the cancer cell uptake of FA-MOFs. The synthesis of redox-responsive dual-drug delivery MOF hybrids paves the way to assemble of other MOF hybrids that respond to other triggering factors such as light, temperature, pH, or biomarkers. The properties and functions of such materials are expected to influence the development of sensors, new catalysts, photonic devices, and drug delivery carriers.

show abstract

Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy

Abstract: Doxorubicin–paclitaxel prodrug nanoparticles with redox-responsive were synthesized to selectively inhibit cancer cells with reduced adverse drug effect to healthy cells.

Cited by 55 publications

References 51 publications

Engineering small molecule nanodrugs to overcome barriers for cancer therapy

Engineering small molecule nanodrugs to overcome barriers for cancer therapy

Immunotherapeutic silk inverse opal particles for post-surgical tumor treatment

Redox-Responsive Tumor Targeted Dual-Drug Loaded Biocompatible Metal-Organic Frameworks for Enhancing Anticancer Cytotoxicity

Contact Info

Product

Resources

About